Navigation Links
Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
Date:5/18/2012

MORRISTOWN, N.J., May 18, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip® XL.  Actavis believes this is the first generic Requip® XL available in the US.  Distribution of the product has commenced.  

Requip® XL, 2mg, 4mg, 6mg, 8mg and 12mg, had US sales of approximately $59.4 million for the 12 months ending December 31, 2011, according to IMS Health.   

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:

"The launch of Ropinirole Extended-Release Tablets showcases  Actavis' commitment in bringing new products to market to benefit both patients and payors. We are proud to play a part in lowering healthcare costs through the introduction of quality generic products."

 

Inquiries
David Myers, Jr.
Senior Manager, Products & Communications
Tel: (973)993-4503
E-mail: dmyers@actavis.com

About Actavis:
Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

Requip® XL is a registered trademark of a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.

 


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Receives Approval of Alprazolam ODT in the U.S.
2. Actavis Launches Generic Version of Flomax(R) In The U.S.
3. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
4. Actavis Receives Approval of Bupropion HCl SR 100mg and 200mg in the U.S.
5. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
6. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
7. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
8. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
9. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
10. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
11. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
(Date:1/18/2017)...  Robust competition in the private marketplace is ... prices, according to a new study by ... the first to examine the share of prescription medicine ... managers (PBMs), health plans and other stakeholders in the ... first to show what happens when the list price ...
(Date:1/17/2017)... 2017 North America Insulin Delivery Market Outlook ... America Insulin Delivery Market Outlook to 2022", provides key ... The report provides value, in millions of US dollars, ... segments - Insulin Pens, Insulin Pumps, Insulin Syringes and ... company shares and distribution shares data for each of ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... The VA Maryland Health Care ... a research project focused on multiple sclerosis (MS). Led by Christopher M. Jewell, ... control the disease without compromising normal immune function that often occurs during autoimmune ...
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor plans to ... an international charity that provides free surgery to poor children suffering from cleft lip ... past I have run to support the efforts of the American Heart Association and ...
(Date:1/18/2017)... ... ... At Hallmark Nameplate, their commitment to quality is what sets them apart. ... This certification is another way they are making constant strides to provide all customers ... , The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate and will ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... support an aid project with the donation of cochlear implants. In February 2017, ... hearing and thus a fair chance of leading an independent life. This engagement ...
(Date:1/17/2017)... ... 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now in its ... corners and commit the crime of stalking, a very real danger to many in our ... factor in stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads ...
Breaking Medicine News(10 mins):